Serum level of tumor marker carbohydrate antigen-CA125 in heart failure

Azra Durak-Nalbantic1, Nerma Resic2, Mehmed Kulic2

  • 1Clinic for Heart disease and rheumatism, Clinical Center University of Sarajevo, Sarajevo, Bosnia and Herzegovina. azradurak@yahoo.com

Insights

Serum carbohydrate antigen 125 (CA125) is elevated in decompensated heart failure (HF) patients, especially those with effusions. CA125 correlates with brain natriuretic peptide (BNP) and may indicate systemic congestion.

Area of Science:

  • Cardiology
  • Biomarker Research
  • Internal Medicine

Background:

  • Heart failure (HF) diagnosis and management rely on clinical assessment and biomarkers.
  • Brain natriuretic peptide (BNP) is a key biomarker for HF, but its interpretation can be complex.
  • Carbohydrate antigen 125 (CA125) is a tumor marker with potential roles in non-oncological conditions like HF.

Purpose of the Study:

  • To evaluate serum CA125 levels in patients with heart failure.
  • To explore the correlation between CA125, echocardiographic parameters, and BNP levels in HF patients.
  • To determine if CA125 can serve as a marker for systemic congestion in decompensated HF.

Main Methods:

  • Inclusion of 76 patients with cardiac symptoms, divided into HF (n=50) and control (n=26) groups.
  • Subdivision of HF patients into compensated (compHF) and decompensated (decompHF) groups based on fluid overload.
  • Measurement of serum CA125 and BNP, along with ECG and echocardiography, on admission.

Main Results:

  • Significantly higher CA125 levels in HF patients compared to controls (71.05 vs 10.75 U/ml).
  • Elevated CA125 in decompHF (94.90 U/ml) versus compHF (11.90 U/ml) and further increased in patients with pleural/pericardial effusion (205.10 U/ml).
  • Positive correlation between CA125 and BNP (r=0.293, p=0.039); no significant correlation with LVEF or left atrium diameter.

Conclusions:

  • Serum CA125 is elevated in decompensated HF, particularly with serosal effusions.
  • CA125 levels correlate with BNP, suggesting a role in reflecting systemic congestion and volume overload.
  • CA125 may serve as a valuable adjunct marker in assessing decompensated HF, potentially clarifying 'wet' BNP levels.
Abstract

Related Concept Videos

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
765
Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
1.2K
Heart Failure IV: Classification and Diagnostic Evaluation01:30

Heart Failure IV: Classification and Diagnostic Evaluation

Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
1.0K
Heart Failure III: Clinical Manifestations01:26

Heart Failure III: Clinical Manifestations

Heart failure (HF) manifests primarily as dyspnea, fatigue, and fluid retention, resulting in peripheral and pulmonary edema. Symptoms may vary depending on which ventricle is more affected, left or right.Left-Sided Heart FailureAlso known as left ventricular failure, this condition results from the left ventricle's inability to fill or eject sufficient blood into the systemic circulation. It leads to pulmonary congestion, which occurs when the left ventricle fails to eject blood effectively...
1.2K
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
790
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
805